• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阴沟肠杆菌败血症在使用 Seraph-100 Microbind 亲和血液滤器的三腔套管体外膜肺氧合循环支持治疗中。

Enterobacter cloacae septicemia in a triple-cannula extracorporeal membrane oxygenation circulatory support treated with Seraph-100 Microbind affinity blood filter.

机构信息

Marin Pavlov, Department of Cardiology, Dubrava University Hospital, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia,

出版信息

Croat Med J. 2023 Aug 31;64(4):284-288. doi: 10.3325/cmj.2023.64.284.

DOI:10.3325/cmj.2023.64.284
PMID:37654040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509680/
Abstract

Bloodstream infections (BSI) are frequently encountered during extracorporeal membrane oxygenation (ECMO) support. Once septicemia is observed, treatment should be rapid, adequate, and multifaceted, particularly in advanced ECMO configurations. We report on a case of a 60-year-old male patient with acute-on-chronic heart failure due to ischemic cardiomyopathy. The treatment was complicated by cardiogenic shock requiring veno-arterial ECMO support, and, due to persistent pulmonary congestion, an upgrade with an additional left-atrial drainage cannula. After seven days of ECMO support, septicemia with shock ensued. Ex iuvantibus antibiotic treatment was started promptly. We wanted to minimize the likelihood of bacterial biofilm build-up requiring an exchange of the ECMO circuit and cannula, which was expected to be challenging. Therefore, we added a Seraph-100 Microbind affinity blood filter (providing blood purification with the potential for rapid bacterial clearance) to the ECMO circuit. Initial blood cultures tested positive for Enterobacter cloacae. Following a course of Seraph-100 treatment, bacteremia, septicemia, and shock resolved. There was no need for a circuit or cannula exchange. The additional eleven days of ECMO support were uneventful. The patient was successfully bridged to long-term mechanical circulatory support. We believe that the synergistic effect of early implementation of both broad-spectrum antibiotic treatment and blood purification with the potential for rapid bacterial clearance (such as the one provided with the Seraph-100 Microbind affinity blood filter) is crucial in BSI in patients receiving advanced ECMO.

摘要

血流感染(BSI)在外周膜肺氧合(ECMO)支持期间经常发生。一旦观察到败血症,治疗应迅速、充分和多方面,特别是在高级 ECMO 配置中。我们报告了一例 60 岁男性患者,因缺血性心肌病导致急性失代偿性心力衰竭。由于心源性休克需要静脉动脉 ECMO 支持,治疗变得复杂,并且由于持续的肺充血,需要升级并增加一个左心房引流管。在 ECMO 支持七天后,出现败血症性休克。立即开始经验性抗生素治疗。我们希望尽量减少需要更换 ECMO 回路和导管以避免细菌生物膜积聚的可能性,预计这将具有挑战性。因此,我们在 ECMO 回路中添加了 Seraph-100 Microbind 亲和血液过滤器(提供血液净化并具有快速清除细菌的潜力)。最初的血液培养物检测出阴沟肠杆菌阳性。经过 Seraph-100 治疗后,菌血症、败血症和休克得到缓解。无需更换回路或导管。另外十一天的 ECMO 支持没有出现问题。患者成功地过渡到长期机械循环支持。我们认为,在接受高级 ECMO 的患者中,早期实施广谱抗生素治疗和血液净化(如 Seraph-100 Microbind 亲和血液过滤器提供的治疗)并具有快速清除细菌的潜力的协同作用至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/0199e9fbf71b/CroatMedJ_64_0284-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/e7ced85f7270/CroatMedJ_64_0284-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/d174b25c5881/CroatMedJ_64_0284-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/0199e9fbf71b/CroatMedJ_64_0284-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/e7ced85f7270/CroatMedJ_64_0284-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/d174b25c5881/CroatMedJ_64_0284-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/366b/10509680/0199e9fbf71b/CroatMedJ_64_0284-F3.jpg

相似文献

1
Enterobacter cloacae septicemia in a triple-cannula extracorporeal membrane oxygenation circulatory support treated with Seraph-100 Microbind affinity blood filter.阴沟肠杆菌败血症在使用 Seraph-100 Microbind 亲和血液滤器的三腔套管体外膜肺氧合循环支持治疗中。
Croat Med J. 2023 Aug 31;64(4):284-288. doi: 10.3325/cmj.2023.64.284.
2
Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study.Seraph® 100 Microbind® Affinity 血液滤器清除血流中细菌的安全性和有效性:首例人体研究结果。
Crit Care. 2022 Jun 17;26(1):181. doi: 10.1186/s13054-022-04044-7.
3
Position of draining venous cannula in extracorporeal membrane oxygenation for respiratory and respiratory/circulatory support in adult patients.体外膜肺氧合中用于成人呼吸和呼吸/循环支持的静脉引流管位置。
Crit Care. 2018 Jun 15;22(1):163. doi: 10.1186/s13054-018-2083-0.
4
Single-Center Experience With the Seraph-100® Microbind® Affinity Blood Filter in Patients With SARS-CoV-2 Infection and Septic Shock at a Military Treatment Facility.在一家军事治疗机构中,使用Seraph-100® Microbind®亲和性血液滤过器治疗感染新型冠状病毒肺炎且患有感染性休克患者的单中心经验。
Mil Med. 2023 Jul 22;188(7-8):e2670-e2674. doi: 10.1093/milmed/usad063.
5
Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock.心源性休克患者接受静脉-动脉体外膜肺氧合时肺充血的预防与治疗
Eur Heart J. 2020 Oct 7;41(38):3753-3761. doi: 10.1093/eurheartj/ehaa547.
6
Veno-arteriovenous extracorporeal membrane oxygenation-A single center experience.静脉-动脉体外膜肺氧合——单中心经验。
Artif Organs. 2021 Dec;45(12):1554-1561. doi: 10.1111/aor.14070. Epub 2021 Sep 22.
7
Extracorporeal lung support technologies - bridge to recovery and bridge to lung transplantation in adult patients: an evidence-based analysis.体外肺支持技术——成人患者的康复桥梁和肺移植桥梁:一项基于证据的分析
Ont Health Technol Assess Ser. 2010;10(5):1-47. Epub 2010 Apr 1.
8
Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors.难治性心源性休克的体外膜肺氧合支持:治疗策略及危险因素分析
Artif Organs. 2014 Jul;38(7):E129-41. doi: 10.1111/aor.12317. Epub 2014 May 20.
9
An experimental model of veno-venous arterial extracorporeal membrane oxygenation.静脉-静脉动脉体外膜肺氧合的实验模型
Int J Artif Organs. 2020 Apr;43(4):268-276. doi: 10.1177/0391398819882024. Epub 2019 Nov 6.
10
Outcomes of patients with acute respiratory failure on veno-venous extracorporeal membrane oxygenation requiring additional circulatory support by veno-venoarterial extracorporeal membrane oxygenation.接受静脉-静脉体外膜肺氧合治疗的急性呼吸衰竭患者,若需要通过静脉-静脉-动脉体外膜肺氧合获得额外循环支持的治疗结果。
Front Med (Lausanne). 2022 Sep 23;9:1000084. doi: 10.3389/fmed.2022.1000084. eCollection 2022.

引用本文的文献

1
[Extracorporeal removal of pathogens using a biomimetic adsorber-A new treatment strategy for the intensive care unit : Seraph® 100 Microbind® Affinity Blood Filter and its fields of application].[使用仿生吸附剂进行病原体的体外清除——重症监护病房的一种新治疗策略:Seraph® 100 Microbind® 亲和性血液滤器及其应用领域]
Med Klin Intensivmed Notfmed. 2025 May;120(4):290-299. doi: 10.1007/s00063-024-01153-9. Epub 2024 Jul 10.
2
Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.链球菌中毒性休克综合征患者在静脉-动脉体外膜肺氧合治疗无效后,序贯采用病原体清除体外治疗和细胞导向体外治疗:一例报告
Crit Care Explor. 2024 Feb 26;6(3):e1058. doi: 10.1097/CCE.0000000000001058. eCollection 2024 Mar.

本文引用的文献

1
Bloodstream infection and ventilator-associated pneumonia in patients with coronavirus disease 2019 (COVID-19) supported by extracorporeal membrane oxygenation.COVID-19 患者体外膜肺氧合支持下的血流感染和呼吸机相关性肺炎。
Infect Control Hosp Epidemiol. 2023 Sep;44(9):1443-1450. doi: 10.1017/ice.2022.290. Epub 2022 Dec 1.
2
Clinical and microbiological characteristics of and risk factors for bloodstream infections among patients with extracorporeal membrane oxygenation: a single-center retrospective cohort study.体外膜肺氧合患者血流感染的临床和微生物学特征及危险因素:一项单中心回顾性队列研究。
Sci Rep. 2022 Sep 5;12(1):15059. doi: 10.1038/s41598-022-19405-z.
3
Hemoperfusion: technical aspects and state of the art.
血液灌流:技术层面与最新进展。
Crit Care. 2022 May 12;26(1):135. doi: 10.1186/s13054-022-04009-w.
4
Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.使用Seraph 100微结合亲和血液过滤器进行血液灌流不太可能需要增加抗生素剂量:一项采用药代动力学/药效学方法的模拟研究。
Blood Purif. 2023;52(1):25-31. doi: 10.1159/000524457. Epub 2022 May 6.
5
Analysis of Nosocomial Infection and Risk Factors in Patients with ECMO Treatment.体外膜肺氧合治疗患者医院感染及危险因素分析
Infect Drug Resist. 2021 Jun 25;14:2403-2410. doi: 10.2147/IDR.S306209. eCollection 2021.
6
Elimination of from the bloodstream using a novel biomimetic sorbent haemoperfusion device.使用新型仿生吸附剂血液灌流器清除血液中的 。
BMJ Case Rep. 2020 Aug 24;13(8):e235262. doi: 10.1136/bcr-2020-235262.
7
Heparin 2.0: A New Approach to the Infection Crisis.肝素 2.0:应对感染危机的新方法。
Blood Purif. 2021;50(1):28-34. doi: 10.1159/000508647. Epub 2020 Jul 2.
8
Infection and colonisation in V-V ECMO-not a predictor of poor outcome.静脉-静脉体外膜肺氧合中的感染与定植——并非预后不良的预测因素。
J Thorac Dis. 2018 Jun;10(Suppl 17):S2045-S2047. doi: 10.21037/jtd.2018.05.128.
9
Efficacy of Linezolid and Fosfomycin in Catheter-Related Biofilm Infection Caused by Methicillin-Resistant Staphylococcus aureus.利奈唑胺和磷霉素对耐甲氧西林金黄色葡萄球菌引起的导管相关生物膜感染的疗效
Biomed Res Int. 2016;2016:6413982. doi: 10.1155/2016/6413982. Epub 2016 Jun 5.
10
Impact of bloodstream infections on catheter colonization during extracorporeal membrane oxygenation.体外膜肺氧合期间血流感染对导管定植的影响。
J Artif Organs. 2016 Jun;19(2):128-33. doi: 10.1007/s10047-015-0882-5. Epub 2015 Dec 31.